Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash from Investing Activities (2016 - 2023)

Rein Therapeutics (RNTX) has disclosed Cash from Investing Activities for 8 consecutive years, with -$96000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Cash from Investing Activities fell 102.02% to -$96000.0 in Q4 2023 year-over-year; TTM through Sep 2024 was -$96000.0, a 100.46% decrease, with the full-year FY2023 number at $16.2 million, down 38.79% from a year prior.
  • Cash from Investing Activities was -$96000.0 for Q4 2023 at Rein Therapeutics, down from $542000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $11.6 million in Q1 2022 to a low of -$37.5 million in Q1 2021.
  • A 5-year average of $516750.0 and a median of $3.9 million in 2019 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 730.53% in 2021; the steepest drop was 2107.53% in 2021.
  • Rein Therapeutics' Cash from Investing Activities stood at $4.8 million in 2019, then plummeted by 107.49% to -$357000.0 in 2020, then skyrocketed by 730.53% to $2.3 million in 2021, then soared by 111.64% to $4.8 million in 2022, then crashed by 102.02% to -$96000.0 in 2023.
  • Per Business Quant, the three most recent readings for RNTX's Cash from Investing Activities are -$96000.0 (Q4 2023), $542000.0 (Q3 2023), and $8.5 million (Q2 2023).